Patents by Inventor Luis Javier Cruz Ricondo

Luis Javier Cruz Ricondo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11185600
    Abstract: The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultrasound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.
    Type: Grant
    Filed: September 14, 2013
    Date of Patent: November 30, 2021
    Assignee: STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
    Inventors: Carl Gustav Figdor, Ingrid Jolanda Monique De Vries, Mangala Srinivas, Luis Javier Cruz Ricondo, Christoffel Leendert De Korte
  • Publication number: 20200230164
    Abstract: The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as ? Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3-dendritic cells.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 23, 2020
    Inventors: Francois TROTTEIN, Christelle FAVEEUW, Elodie MACHO FERNANDEZ, Luis Javier CRUZ RICONDO
  • Publication number: 20180258140
    Abstract: The present invention relates to targeted microcapsules comprising a skin aging compound to target fibroblast with a peptide, which is a FGF receptor agonist, wherein said peptide is coupled to the outer surface of the microcapsule. It also relates to the use of said microcapsules for the cosmetic prevention and/or cosmetic treatment of cutaneous effects of skin aging and to the cosmetic compositions comprising said microcapsules. The invention also relates to the FGF receptor agonist peptide coupled to the microcapsule.
    Type: Application
    Filed: February 24, 2016
    Publication date: September 13, 2018
    Inventors: Marisabel Mourelle Mancini, Luis Javier Cruz Ricondo, Magdalena Carceller Margeli
  • Patent number: 9745346
    Abstract: The present invention relates to a compound of formula (I) and to compositions comprising said compound, as well as the use of said compound and/or said compositions to prevent fungal and/or bacterial growth.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: August 29, 2017
    Assignee: INFINITEC ACTIVOS S.L
    Inventors: Marisabel Mourelle Mancini, Magdalena Carceller Margeli, Luis Javier Cruz Ricondo
  • Publication number: 20170081364
    Abstract: The present invention relates to a compound of formula (I) and to compositions comprising said compound, as well as the use of said compound and/or said compositions to prevent fungal and/or bacterial growth.
    Type: Application
    Filed: March 10, 2015
    Publication date: March 23, 2017
    Applicant: INFINITEC ACTIVOS S.L.
    Inventors: Marisabel Mourelle Mancini, Magdalena Carceller Margeli, Luis Javier Cruz Ricondo
  • Publication number: 20150374734
    Abstract: The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as ? Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells.
    Type: Application
    Filed: February 20, 2014
    Publication date: December 31, 2015
    Inventors: Francois TROTTEIN, Christelle FAVEEUW, Elodie MACHO FERNANDEZ, Luis Javier CRUZ RICONDO
  • Publication number: 20150250905
    Abstract: The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultra-sound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.
    Type: Application
    Filed: September 14, 2013
    Publication date: September 10, 2015
    Inventors: Carl Gustav Figdor, Ingrid Jolanda Monique De Vries, Mangala Srinivas, Luis Javier Cruz Ricondo
  • Publication number: 20090104223
    Abstract: The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions.
    Type: Application
    Filed: October 10, 2007
    Publication date: April 23, 2009
    Inventors: Julio Cesar Aguilar Rubido, Eduardo Penton Arias, Dina Tleugabulova, Minerva Sewer Mensies, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Iloki Assanga Simon Bernard, Luis Javier Cruz Ricondo, Viviana Falcon Cama, Yanet Tambara Hernandez
  • Publication number: 20040202676
    Abstract: The present invention is related to the method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions.
    Type: Application
    Filed: March 1, 2004
    Publication date: October 14, 2004
    Inventors: Julio Cesar Aguilar Rubido, Eduardo Penton Arias, Dina Tleugabulova, Minerva Sewer Mensies, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Iloki Assanga Simon Bernard, Luis Javier Cruz Ricondo, Viviana Falcon Cama, Yanet Tambara Hernandez
  • Patent number: 6355414
    Abstract: The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: March 12, 2002
    Assignee: Centro de Ingenieria Genetica y Biotechnologia
    Inventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Maria de Jesus Leal Angulo, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Gloria Veliz Rios, Dagmara Pichardo Diaz, Antonieta Herrera Buch, Enrique Iglesias Perez, Luis Javier Cruz Ricondo, Tania Carmenate Portilla, Cirse Mesa Pardillo, Maydel Hechavarria Gay, Maylin Diaz Martinez, Juan Joel Madrazo PiƱol